Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 12/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.33 |
| ▸ | CCKBR | P32239 | 2/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.33 |
| ▸ | GMNN | O75496 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.33 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL312750 | 0.83 | CYP11B1 (0.43) | CYP11B1CYP11B2ENPP2SIRT2TSHR | |
| SCHEMBL8687555 | 0.81 | CYP11B1 (0.42) | CYP11B1CYP11B2ENPP2SIRT2TSHR | |
| SCHEMBL26704592 | 0.81 | KDM4E (0.44) | CYP11B1CYP11B2ENPP2TSHRMEN1 | |
| SCHEMBL7621404 | 0.79 | CYP11B1 (0.40) | CYP11B1CYP11B2ENPP2SIRT2TSHR | |
| SCHEMBL7684568 | 0.79 | CYP11B1 (0.40) | CYP11B1CYP11B2ENPP2SIRT2TSHR | |
| SCHEMBL7684566 | 0.79 | CYP11B1 (0.40) | CYP11B1CYP11B2ENPP2SIRT2TSHR | |
| SCHEMBL7453723 | 0.78 | CYP11B1 (0.39) | CYP11B1CYP11B2ENPP2SIRT2TSHR | |
| SCHEMBL6714980 | 0.78 | RAB9A (0.42) | CYP11B1CYP11B2ENPP2SIRT2MEN1 | |
| SCHEMBL9547333 | 0.78 | CYP11B1 (0.39) | CYP11B1CYP11B2ENPP2SIRT2TSHR | |
| SCHEMBL6714982 | 0.78 | RAB9A (0.42) | CYP11B1CYP11B2ENPP2SIRT2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150297596-A1 | ISOXAZOLINES AS THERAPEUTIC AGENTS | ABBVIE INC. (US) | 2015-10-22 | — | — | US | disclosed |
| US-9029409-B2 | Isoxazolines as therapeutic agents | ABBVIE INC. (US) | 2015-05-12 | — | — | US | disclosed |
| CN-103764145-A | Isoxazolines as therapeutic agents | ABBOTT LAB | 2014-04-30 | — | — | CN | disclosed |
| EP-2704712-A1 | ISOXAZOLINES AS THERAPEUTIC AGENTS | AbbVie Inc. (US) | 2014-03-12 | — | — | EP | disclosed |
| US-20130023526-A1 | Isoxazolines as Therapeutic Agents | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | US | disclosed |
| WO-2012151158-A1 | ISOXAZOLINES AS THERAPEUTIC AGENTS | ABBOTT LABORATORIES (US) | 2012-11-08 | — | — | WO | disclosed |
| EP-2225209-B1 | PROCESS FOR THE PREPARATION OF 5-(2-ETHYL-DIHYDRO-1H-INDEN-2-YL)-1H-IMIDAZOLE AND SALTS THEREOF | GRINDEKS JSC (LV) | 2012-03-28 | — | — | EP | disclosed |
| WO-2009093981-A1 | TRIAZINE COMPOUNDS AS KINASE INHIBITORS | S BIO PTE LTD (SG) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009093981-A1 | TRIAZINE COMPOUNDS AS KINASE INHIBITORS | S BIO PTE LTD (SG) | 2009-07-30 | — | — | WO | disclosed |
| CN-1814614-A | Nucleic acid, peptide nucleicacid derivatives and their use | TOXIC MEDICINE INST MILITARY M (CN) | 2006-08-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150297596-A1 | ISOXAZOLINES AS THERAPEUTIC AGENTS | CYP3A7, CYP11B2, CYP11B1 | CYP11B1 3/4885CYP11B2 2/4885ENPP2 416/4885 |
| US-20130023526-A1 | Isoxazolines as Therapeutic Agents | CYP3A7, CYP11B2, CYP11B1 | CYP11B1 3/4885CYP11B2 2/4885ENPP2 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.